{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:11:27Z","timestamp":1790993487935,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFC3601800"],"award-info":[{"award-number":["2022YFC3601800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Special Program of National Natural Science Foundation of China","award":["NO. 32141004"],"award-info":[{"award-number":["NO. 32141004"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["No.2021-I2M-1-059"],"award-info":[{"award-number":["No.2021-I2M-1-059"]}]},{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2020-RC320-003"],"award-info":[{"award-number":["2020-RC320-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10067-024-07236-4","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T05:20:25Z","timestamp":1732339225000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The importance of developing reproducible primary endpoints for clinical trials in systemic lupus erythematosus"],"prefix":"10.1007","volume":"44","author":[{"given":"Bingyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-1712","authenticated-orcid":false,"given":"Jiao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"key":"7236_CR1","doi-asserted-by":"publisher","unstructured":"Atisha-Fregoso Y, Toz B, Diamond B (2021) Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Invest 131 https:\/\/doi.org\/10.1172\/JCI149095","DOI":"10.1172\/JCI149095"},{"key":"7236_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12016-020-08798-2","volume":"59","author":"J Jiang","year":"2020","unstructured":"Jiang J, Zhao M, Chang C, Wu H, Lu Q (2020) Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases. Clinical reviews in allergy & immunology 59:248\u2013272","journal-title":"Clinical reviews in allergy & immunology"},{"key":"7236_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","volume":"17","author":"R Felten","year":"2018","unstructured":"Felten R et al (2018) The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. Autoimmun Rev 17:781\u2013790. https:\/\/doi.org\/10.1016\/j.autrev.2018.02.011","journal-title":"Autoimmun Rev"},{"issue":"Suppl 1","key":"7236_CR4","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar3910","volume":"15","author":"V Reddy","year":"2013","unstructured":"Reddy V, Jayne D, Close D, Isenberg D (2013) B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 15(Suppl 1):S2. https:\/\/doi.org\/10.1186\/ar3910","journal-title":"Arthritis Res Ther"},{"key":"7236_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11926-018-0745-1","volume":"20","author":"A Thanou","year":"2018","unstructured":"Thanou A, Merrill JT (2018) New trials in lupus and where are we going. Curr Rheumatol Rep 20:34. https:\/\/doi.org\/10.1007\/s11926-018-0745-1","journal-title":"Curr Rheumatol Rep"},{"key":"7236_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/art.24698","volume":"61","author":"RA Furie","year":"2009","unstructured":"Furie RA et al (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61:1143\u20131151. https:\/\/doi.org\/10.1002\/art.24698","journal-title":"Arthritis Rheum"},{"issue":"Suppl 11","key":"7236_CR7","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1002\/acr.20572","volume":"63","author":"J Romero-Diaz","year":"2011","unstructured":"Romero-Diaz J, Isenberg D, Ramsey-Goldman R (2011) Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index (SDI). Arthritis Care Res (Hoboken) 63(Suppl 11):S37-46. https:\/\/doi.org\/10.1002\/acr.20572","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"7236_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT et al (2018) Efficacy and Safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol 70:266\u2013276. https:\/\/doi.org\/10.1002\/art.40360","journal-title":"Arthritis Rheumatol"},{"key":"7236_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630\u2013640. https:\/\/doi.org\/10.1002\/art.1780350606","journal-title":"Arthritis Rheum"},{"issue":"1","key":"7236_CR10","doi-asserted-by":"publisher","first-page":"e000365","DOI":"10.1136\/lupus-2019-000365","volume":"6","author":"A Thanou","year":"2019","unstructured":"Thanou A, James JA, Arriens C, Aberle T, Chakravarty E, Rawdon J, Stavrakis S, Merrill JT, Askanase A (2019) Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. Lupus Sci Med 6(1):e000365. https:\/\/doi.org\/10.1136\/lupus-2019-000365","journal-title":"Lupus Sci Med"},{"key":"7236_CR11","first-page":"S-85","volume":"32","author":"I Castrejon","year":"2014","unstructured":"Castrejon I, Tani C, Jolly M, Huang A, Mosca M (2014) Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol 32:S-85-95","journal-title":"Clin Exp Rheumatol"},{"key":"7236_CR12","doi-asserted-by":"publisher","first-page":"e000266","DOI":"10.1136\/lupus-2018-000266","volume":"5","author":"M Kim","year":"2018","unstructured":"Kim M, Merrill JT, Kalunian K, Hanrahan L, Izmirly P (2018) Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials. Lupus Sci Med 5:e000266. https:\/\/doi.org\/10.1136\/lupus-2018-000266","journal-title":"Lupus Sci Med"},{"key":"7236_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382:211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"key":"7236_CR14","first-page":"927","volume":"69","author":"DP Symmons","year":"1988","unstructured":"Symmons DP et al (1988) Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 69:927\u2013937","journal-title":"Q J Med"},{"key":"7236_CR15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/rheumatology\/kev387","volume":"55","author":"CL Murphy","year":"2016","unstructured":"Murphy CL, Yee CS, Gordon C, Isenberg D (2016) From BILAG to BILAG-based combined lupus assessment-30 years on. Rheumatology (Oxford) 55:1357\u20131363. https:\/\/doi.org\/10.1093\/rheumatology\/kev387","journal-title":"Rheumatology (Oxford)"},{"key":"7236_CR16","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1002\/art.22162","volume":"54","author":"CS Yee","year":"2006","unstructured":"Yee CS et al (2006) Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 54:3300\u20133305. https:\/\/doi.org\/10.1002\/art.22162","journal-title":"Arthritis Rheum"},{"key":"7236_CR17","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/rheumatology\/keq026","volume":"49","author":"CS Yee","year":"2010","unstructured":"Yee CS et al (2010) Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) 49:1665\u20131669. https:\/\/doi.org\/10.1093\/rheumatology\/keq026","journal-title":"Rheumatology (Oxford)"},{"key":"7236_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","volume":"73","author":"DJ Wallace","year":"2014","unstructured":"Wallace DJ et al (2014) Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73:183\u2013190. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202760","journal-title":"Ann Rheum Dis"},{"key":"7236_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/rheumatology\/kep064","volume":"48","author":"CS Yee","year":"2009","unstructured":"Yee CS et al (2009) The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 48:691\u2013695. https:\/\/doi.org\/10.1093\/rheumatology\/kep064","journal-title":"Rheumatology (Oxford)"},{"key":"7236_CR20","doi-asserted-by":"publisher","unstructured":"Furie R et al (2021) What does it mean to be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment responder? Post hoc analysis of 2 phase 3 trials. Arthritis Rheumatol.\u00a0https:\/\/doi.org\/10.1002\/art.41778","DOI":"10.1002\/art.41778"},{"key":"7236_CR21","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/anr.1780320909","volume":"32","author":"MH Liang","year":"1989","unstructured":"Liang MH, Socher SA, Larson MG, Schur PH (1989) Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107\u20131118. https:\/\/doi.org\/10.1002\/anr.1780320909","journal-title":"Arthritis Rheum"},{"key":"7236_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.berh.2005.03.010","volume":"19","author":"B Griffiths","year":"2005","unstructured":"Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19:685\u2013708. https:\/\/doi.org\/10.1016\/j.berh.2005.03.010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"7236_CR23","doi-asserted-by":"publisher","unstructured":"Ugarte-Gil MF et al (2020) Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. Lupus Sci Med 7.\u00a0https:\/\/doi.org\/10.1136\/lupus-2020-000419","DOI":"10.1136\/lupus-2020-000419"},{"key":"7236_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/annrheumdis-2018-214502","volume":"78","author":"D Jesus","year":"2019","unstructured":"Jesus D et al (2019) Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis 78:365\u2013371. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214502","journal-title":"Ann Rheum Dis"},{"key":"7236_CR25","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1136\/annrheumdis-2019-215704","volume":"79","author":"A Mathew","year":"2020","unstructured":"Mathew A, Chengappa KG, Shah S, Negi VS (2020) SLE-DAS: ready for routine use? Ann Rheum Dis 79:e116. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215704","journal-title":"Ann Rheum Dis"},{"key":"7236_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT (2021) Update omicronn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80:14\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218272","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07236-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07236-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07236-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T13:40:05Z","timestamp":1736775605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07236-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7236"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07236-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,23]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}